EA202091464A1 - Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита - Google Patents

Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита

Info

Publication number
EA202091464A1
EA202091464A1 EA202091464A EA202091464A EA202091464A1 EA 202091464 A1 EA202091464 A1 EA 202091464A1 EA 202091464 A EA202091464 A EA 202091464A EA 202091464 A EA202091464 A EA 202091464A EA 202091464 A1 EA202091464 A1 EA 202091464A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alcoholic
treatment
liver disease
compositions
fat liver
Prior art date
Application number
EA202091464A
Other languages
English (en)
Russian (ru)
Inventor
Майкл Оливер Торнер
Рой Г. Смит
Original Assignee
Люмос Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Люмос Фарма, Инк. filed Critical Люмос Фарма, Инк.
Publication of EA202091464A1 publication Critical patent/EA202091464A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA202091464A 2018-02-14 2019-02-14 Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита EA202091464A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862630361P 2018-02-14 2018-02-14
PCT/US2019/017964 WO2019161025A1 (en) 2018-02-14 2019-02-14 Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
EA202091464A1 true EA202091464A1 (ru) 2020-12-07

Family

ID=67620042

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091464A EA202091464A1 (ru) 2018-02-14 2019-02-14 Композиции для лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита

Country Status (10)

Country Link
US (3) US20210059993A1 (enExample)
EP (3) EP4467158A3 (enExample)
JP (3) JP2021513552A (enExample)
KR (2) KR20240015742A (enExample)
CN (2) CN118453597A (enExample)
AU (2) AU2019222736B2 (enExample)
BR (1) BR112020016613A2 (enExample)
CA (1) CA3088177A1 (enExample)
EA (1) EA202091464A1 (enExample)
WO (1) WO2019161025A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020205498A1 (en) * 2019-03-29 2020-10-08 The General Hospital Corporation Ghrh or analogues thereof for use in treatment of hepatic disease
CA3192690A1 (en) * 2020-09-18 2022-03-24 Seung Yong Seong Pharmaceutical composition for treating nonalcoholic steatohepatitis and liver fibrosis
KR20220132312A (ko) 2021-03-23 2022-09-30 한국과학기술원 간세포의 IFN-γR1 매개 지질생성작용 억제를 통한 비알코올성 지방간 질환의 치료 방법
GEAP202516774A (en) 2022-11-03 2025-06-25 Lumos Pharma Inc Compactable oral formulations of ibutamoren
WO2025193784A1 (en) * 2024-03-12 2025-09-18 Lumos Pharma, Inc. Pharmaceutical formulations for maintaining lean muscle mass during weight loss treatment
WO2025217521A1 (en) * 2024-04-12 2025-10-16 Jnana Therapeutics Inc. Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist
CN119405782A (zh) * 2025-01-06 2025-02-11 山东大学 胰岛素样生长因子结合蛋白-1在制备治疗非酒精性脂肪性肝病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US20070123470A1 (en) * 2003-10-24 2007-05-31 Wladimir Hogenhuis Enhancement of growth hormone levels with a dipeptidyl peptidase IV inhibitor and a growth hormone secretagogue
JP2007532495A (ja) * 2004-04-07 2007-11-15 ガストロテック・ファルマ・アクティーゼルスカブ グレリン欠乏を治療するための分泌促進薬の使用
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
RU2018113437A (ru) * 2015-09-16 2019-10-17 Тобира Терапьютикс, Инк. Комбинированная терапия с использованием ценикривирока для лечения фиброза
WO2019008554A1 (en) * 2017-07-06 2019-01-10 Conte Anthony METHOD FOR ORAL TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE

Also Published As

Publication number Publication date
AU2019222736A1 (en) 2020-07-30
AU2019222736B2 (en) 2024-08-01
CN111727041A (zh) 2020-09-29
BR112020016613A2 (pt) 2020-12-22
JP2021513552A (ja) 2021-05-27
US20210059993A1 (en) 2021-03-04
KR20240015742A (ko) 2024-02-05
EP4467158A2 (en) 2024-11-27
WO2019161025A1 (en) 2019-08-22
EP4623929A3 (en) 2025-12-17
EP3781158A4 (en) 2022-03-16
KR20200121308A (ko) 2020-10-23
AU2024205599A1 (en) 2024-08-22
US20230381158A1 (en) 2023-11-30
EP3781158A1 (en) 2021-02-24
CN118453597A (zh) 2024-08-09
EP4623929A2 (en) 2025-10-01
US20250281470A1 (en) 2025-09-11
EP4467158A3 (en) 2025-02-19
JP2025179056A (ja) 2025-12-09
CA3088177A1 (en) 2019-08-22
JP2024028337A (ja) 2024-03-04

Similar Documents

Publication Publication Date Title
EP4623929A3 (en) Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
EA202091290A1 (ru) Аналоги инкретина и их применение
EA202091284A1 (ru) Аналоги инкретина и их применение
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
MX2023008330A (es) Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
MX2018005193A (es) Proteinas de doble funcion y composicion farmaceutica que comprende las mismas.
MX2020007410A (es) Formulaciones, composiciones y métodos farmacéuticos de péptido yy.
JOP20210089A1 (ar) نظائر بروتين تيروسين-تيروسين وطرق لاستخدامها
MX391804B (es) Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas.
MX2023014771A (es) Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
EA200701705A1 (ru) Антагонисты рецепторы глюкагона, получение и терапевтическое применение
MX2021015651A (es) Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
MX2020010547A (es) Anticuerpo agonista del receptor de leptina para usarse en el tratamiento de una disfuncion metabolica o hipoleptinemia.
ZA202109182B (en) Natriuretic peptide receptor 1 antibodies and methods of use
MX376312B (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash
CO2020012621A2 (es) Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso
MX2021008010A (es) Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
MX2025015078A (es) Formulaciones de analogos peptidicos de oxintomodulina
MX2022000388A (es) Terapia de combinacion de agonista de gpr119 e inhibidores de dpp-4.
WO2020225799A3 (en) A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein
Hasib et al. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln
ECSP20014569A (es) Métodos para el tratamiento de enfermedades relacionadas con tnf - alfa
MX2022007929A (es) Coagonistas de triazol grapados de los receptores de glucagon y glp-1.
PH12022552778A1 (en) Glucagon analogues as long-acting glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis